ACE-031
Also known as: ACVR2B-Fc, Myostatin Inhibitor
Key Facts: ACE-031
- Category
- Hormonal
- FDA Status
- Not FDA Approved
- Clinical Status
- Development halted - Safety concerns
- Administration
- Subcutaneous injection
- Typical Dose
- Limited community data available
- Frequency
- See research protocols
- Evidence Level
- Animal Studies
- Duration
- Trials discontinued
What to Expect
A soluble activin receptor that traps myostatin. Developed for muscular dystrophy but trials halted due to safety concerns.
Mechanism of Action
ACE-031 is a fusion protein combining the activin IIB receptor with antibody Fc domain. It acts as a decoy receptor, binding and neutralizing myostatin, GDF11, and activins to promote muscle growth.
Research Summary
Phase II trials in Duchenne MD showed significant muscle mass increase but were halted due to nosebleeds and gum bleeding. The broad ligand binding may cause unwanted vascular effects.
Dosing Information
Note: Animal study doses may not translate directly to humans.
Typical Dosingⓘ
Community experience
Limited community data available
See research dosing
See research protocols
Research Dosingⓘ
Scientific studies
From clinical trials before discontinuation
Doses from Studies
0.5-3 mg/kg every 2 weeks in trials
Duration
Trials discontinued
Administration
Subcutaneous injection
Timing & Administration
Best Time to Take
Morning, same day each week
Once weekly
Food Recommendation
With or without food
Why This Timing?
ACE-031 is a myostatin inhibitor with weekly dosing. Morning allows for monitoring.
Possible Side Effects
Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.
- ●Nosebleeds
- ●Gum bleeding
- ●Spider veins (telangiectasias)
- ●Injection site reactions
- ●FSH level decrease
- ●Clinical trials discontinued due to safety
References
Related Peptides
Peptides commonly compared with ACE-031 or used in similar applications.
Kisspeptin
Clinical TrialsA neuropeptide that plays a critical role in initiating puberty and regulating the reproductive hormone axis. Being studied for fertility and hormonal disorders.
HormonalMOTS-c
PreclinicalA mitochondria-derived peptide that regulates metabolic homeostasis. Discovered in 2015, it's being studied for its effects on insulin sensitivity, exercise capacity, and aging.
HormonalOxytocin
FDAA naturally occurring peptide hormone crucial for social bonding, childbirth, and lactation. Being studied for autism, anxiety, and social disorders.
HormonalGonadorelin
FDAA synthetic version of gonadotropin-releasing hormone. Used diagnostically and therapeutically for various reproductive and hormonal conditions.
HormonalLeuprolide
FDAA GnRH agonist that suppresses testosterone and estrogen production. FDA approved for prostate cancer, endometriosis, uterine fibroids, and precocious puberty.
HormonalDesmopressin
FDAA synthetic analog of vasopressin (ADH) used for diabetes insipidus, bedwetting, and bleeding disorders. Does not cause vasoconstriction like natural vasopressin.
HormonalWant updates on ACE-031 research?
Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.
Educational Information Only
This information is provided for educational purposes only and is not intended as medical advice. Always consult with qualified healthcare providers before making any decisions about peptides or other substances. The protocols listed reflect doses observed in research studies, not recommendations.